Study of Adiponectin Promotor Methylation status in patients with Non Alcoholic Fatty Liver Disease

Abd El-moaty, M.A.; Elsayed, I.A.; Saad, Y.; Eliwa, S.K.; Abd El-Maksoud, N.E.

doi:10.21608/bjas.2021.199032

Study of Adiponectin Promotor Methylation status in patients with Non Alcoholic Fatty Liver Disease

Document Type : Original Research Papers

Authors

¹ Medical Biochemistry,Molecular Biology,Dept.,Faculty of Medicine, Benha Univ., Benha, Egypt

² Endemic Medicine , hepatogastroenterology, Dept., Faculty of Medicine, cairoUniv., cairo, Egypt

10.21608/bjas.2021.199032

Abstract

Nonalcoholic fatty liver disease (NAFLD) is one of the most common causes of liver disease globally, and it is likely to overtake alcoholic liver disease as the primary cause of end-stage liver disease in the coming decades. It affects both adults and children. In light of the significant hurdles in the prevention and control of NAFLD, recent research have shown that detecting adiponectin promotor methylation may be useful in NAFLD diagnosis, prognosis, and treatment.. Adiponectin (an adipose tissue hormone) induces apoptosis in hepatocytes, which has an anti-steatotic effect. Several samples from patients with NAFLD have been shown to exhibit adiponectin promotor methylation (NAFLD) so it can be used as non- invasive tool for NAFLD diagnosis.

Keywords